Your browser doesn't support javascript.
loading
Safety and Efficacy of Immune Checkpoint Inhibitors in Patients with Cancer and Viral Hepatitis: The MD Anderson Cancer Center Experience.
Nardo, Mirella; Yilmaz, Bulent; Nelson, Blessie Elizabeth; Torres, Harrys A; Wang, Lan Sun; Granwehr, Bruno Palma; Song, Juhee; Dalla Pria, Hanna R F; Trinh, Van A; Glitza Oliva, Isabella C; Patel, Sapna P; Tannir, Nizar M; Kaseb, Ahmed Omar; Altan, Mehmet; Lee, Sunyoung S; Miller, Ethan; Zhang, Hao; Stephen, Bettzy A; Naing, Aung.
Afiliación
  • Nardo M; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Yilmaz B; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Nelson BE; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Torres HA; Department of Infectious Diseases Infection Control and Employee Health, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Wang LS; Department of Genitourinary Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Granwehr BP; Department of Infectious Diseases Infection Control and Employee Health, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Song J; Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Dalla Pria HRF; Department of Radiology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Trinh VA; Department of Melanoma Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Glitza Oliva IC; Department of Melanoma Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Patel SP; Department of Melanoma Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Tannir NM; Department of Genitourinary Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Kaseb AO; Department of Genitourinary Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Altan M; Department of Genitourinary Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Lee SS; Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston TX, USA.
  • Miller E; Department of Gastrointestinal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Zhang H; Department of Gastrointestinal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Stephen BA; Department of Gastrointestinal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Naing A; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Oncologist ; 28(8): 714-721, 2023 08 03.
Article en En | MEDLINE | ID: mdl-36952233
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Hepatitis Viral Humana / Neoplasias Tipo de estudio: Observational_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: Oncologist Asunto de la revista: NEOPLASIAS Año: 2023 Tipo del documento: Article País de afiliación: Estados Unidos
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Hepatitis Viral Humana / Neoplasias Tipo de estudio: Observational_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: Oncologist Asunto de la revista: NEOPLASIAS Año: 2023 Tipo del documento: Article País de afiliación: Estados Unidos